Radiation Oncology Journal

  • 제33권1호
  • /
  • Pages.29-35
  • /
  • 2015
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Outcome analysis in patients with uterine sarcoma

  • Yu, Tosol (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Kim, Hak Jae (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Wu, Hong-Gyun (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Ha, Sung Whan (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Song, Yong-Sang (Cancer Research Institute, Seoul National University College of Medicine) ;
  • Park, Noh-Hyun (Cancer Research Institute, Seoul National University College of Medicine) ;
  • Kim, Jae-Won (Cancer Research Institute, Seoul National University College of Medicine)
  • 투고 : 2014.10.14
  • 심사 : 2015.02.10
  • 발행 : 2015.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: To analyze the prognostic factors for survivals and to evaluate the impact of postoperative whole pelvic radiotherapy (WPRT) on pelvic failure in patients with uterine sarcoma treated with radical surgery. Materials and Methods: We retrospectively analyzed 75 patients with uterine sarcoma who underwent radical surgery with (n = 22) or without (n = 53) radiotherapy between 1990 and 2010. There were 23 and 52 patients with carcinosarcoma and non-carcinosarcoma (leiomyosarcoma, 22; endometrial stromal sarcoma, 25; others, 5), respectively. The median follow-up period was 64 months (range, 17 to 269 months). Results: The 5-year overall survival (OS) and pelvic failure-free survival (PFFS) of total patients was 64.2% and 83.4%, respectively. Multivariate analysis revealed that mitotic count (p = 0.006) was a significant predictor of OS. However, factors were not found to be associated with PFFS. On analyzing each of the histologic subtypes separately, postoperative WPRT significantly reduced pelvic failure in patients with carcinosarcoma (10.0% vs. 53.7%; p = 0.046), but not in patients with non-carcinosarcoma (12.5% vs. 9.9%; p = 0.866). Among the patients with carcinosarcoma, 4 patients (17%) had recurrence within the pelvis and 3 patients (13%) had recurrence in other sites as an initial failure, whereas among the patients with non-carcinosarcoma, 3 patients (6%) experienced pelvic failure and 13 patients (25%) experienced distant failure. Conclusion: The most significant predictor of OS was mitotic count. Based on the improved PFFS after postoperative WPRT only in patients with carcinosarcoma and the difference in patterns of failure between histologic subtypes, optimal adjuvant treatment options should be offered to patients based on the risk of recurrence patterns.

키워드

참고문헌

  1. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 2004;93:204-8. https://doi.org/10.1016/j.ygyno.2003.12.029
  2. Olah KS, Gee H, Blunt S, Dunn JA, Kelly K, Chan KK. Retrospective analysis of 318 cases of uterine sarcoma. Eur J Cancer 1991;27:1095-9. https://doi.org/10.1016/0277-5379(91)90300-3
  3. Sampath S, Schultheiss TE, Ryu JK, Wong JY. The role of adjuvant radiation in uterine sarcomas. Int J Radiat Oncol Biol Phys 2010;76:728-34. https://doi.org/10.1016/j.ijrobp.2009.02.077
  4. Sorbe B, Johansson B. Prophylactic pelvic irradiation as part of primary therapy in uterine sarcomas. Int J Oncol 2008;32:1111-7.
  5. Ferrer F, Sabater S, Farrus B, et al. Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Grup Oncologic Catala-Occita. Int J Radiat Oncol Biol Phys 1999;44:47-52. https://doi.org/10.1016/S0360-3016(98)00515-X
  6. Reed NS, Mangioni C, Malmstrom H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008;44:808-18. https://doi.org/10.1016/j.ejca.2008.01.019
  7. Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys 2004;58:786-96. https://doi.org/10.1016/S0360-3016(03)01561-X
  8. Denschlag D, Masoud I, Stanimir G, Gilbert L. Prognostic factors and outcome in women with uterine sarcoma. Eur J Surg Oncol 2007;33:91-5. https://doi.org/10.1016/j.ejso.2006.11.012
  9. Vongtama V, Karlen JR, Piver SM, Tsukada Y, Moore RH. Treatment, results and prognostic factors in stage I and II sarcomas of the corpus uteri. AJR Am J Roentgenol 1976;126:139-47. https://doi.org/10.2214/ajr.126.1.139
  10. Moskovic E, MacSweeney E, Law M, Price A. Survival, patterns of spread and prognostic factors in uterine sarcoma: a study of 76 patients. Br J Radiol 1993;66:1009-15. https://doi.org/10.1259/0007-1285-66-791-1009
  11. Tinkler SD, Cowie VJ. Uterine sarcomas: a review of the Edinburgh experience from 1974 to 1992. Br J Radiol 1993;66: 998-1001. https://doi.org/10.1259/0007-1285-66-791-998
  12. Livi L, Andreopoulou E, Shah N, et al. Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998. Clin Oncol (R Coll Radiol) 2004;16:261-8. https://doi.org/10.1016/j.clon.2004.01.010
  13. Sampath S, Gaffney DK. Role of radiotherapy treatment of uterine sarcoma. Best Pract Res Clin Obstet Gynaecol 2011;25: 761-72. https://doi.org/10.1016/j.bpobgyn.2011.06.004
  14. Wolfson AH, Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 2007;107:177-85. https://doi.org/10.1016/j.ygyno.2007.07.070
  15. Chi DS, Mychalczak B, Saigo PE, Rescigno J, Brown CL. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol 1997;65:493-8. https://doi.org/10.1006/gyno.1997.4676
  16. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma: a Gynecologic Oncology Group study. Cancer 1993;71(4 Suppl):1702-9. https://doi.org/10.1002/cncr.2820710440
  17. Gerszten K, Faul C, Kounelis S, Huang Q, Kelley J, Jones MW. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol 1998;68:8-13. https://doi.org/10.1006/gyno.1997.4901
  18. Hornback NB, Omura G, Major FJ. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys 1986;12:2127-30. https://doi.org/10.1016/0360-3016(86)90011-8
  19. Park HJ, Kim HJ, Wu HG, et al. The influence of adjuvant radiotherapy on patterns of failure and survivals in uterine carcinosarcoma. Radiat Oncol J 2011;29:228-35. https://doi.org/10.3857/roj.2011.29.4.228
  20. Brown L, Petersen I, Haddock M, Lee LJ, Cimbak N, Viswanathan A. Vaginal brachytherapy as the sole radiotherapeutic treatment for stage I carcinosarcoma of the uterus. Brachytherapy 2014;13(Suppl 1):S76-S77.
  21. Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987;5:840-50. https://doi.org/10.1200/JCO.1987.5.6.840
  22. Mouridsen HT, Bastholt L, Somers R, et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas: a randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 1987;23:1477-83. https://doi.org/10.1016/0277-5379(87)90089-7
  23. Loehrer PJ Sr, Sledge GW Jr, Nicaise C, et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. J Clin Oncol 1989;7:1655-9. https://doi.org/10.1200/JCO.1989.7.11.1655
  24. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-75. https://doi.org/10.1200/JCO.1993.11.7.1269
  25. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-45. https://doi.org/10.1200/JCO.1995.13.7.1537
  26. Pautier P, Floquet A, Gladieff L, et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study): a study of the French Sarcoma Group. Ann Oncol 2013;24:1099-104. https://doi.org/10.1093/annonc/mds545
  27. Gadducci A, Landoni F, Sartori E, et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol 1996;62:25-32. https://doi.org/10.1006/gyno.1996.0185
  28. Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway: a histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009;54:355-64. https://doi.org/10.1111/j.1365-2559.2009.03231.x
  29. Blom R, Guerrieri C, Stal O, Malmstrom H, Simonsen E. Leiomyosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol 1998;68:54-61. https://doi.org/10.1006/gyno.1997.4889
  30. Ayhan A, Aksan G, Gultekin M, et al. Prognosticators and the role of lymphadenectomy in uterine leiomyosarcomas. Arch Gynecol Obstet 2009;280:79-85. https://doi.org/10.1007/s00404-008-0876-0
  31. Wu TI, Chang TC, Hsueh S, et al. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma. Gynecol Oncol 2006;100:166-72. https://doi.org/10.1016/j.ygyno.2005.08.010
  32. Sorbe B. Radiotherapy and/or chemotherapy as adjuvant treatment of uterine sarcomas. Gynecol Oncol 1985;20:281-9. https://doi.org/10.1016/0090-8258(85)90209-4
  33. Salazar OM, Dunne ME. The role of radiation therapy in the management of uterine sarcomas. Int J Radiat Oncol Biol Phys 1980;6:899-902. https://doi.org/10.1016/0360-3016(80)90334-X

피인용 문헌

  1. An analysis of 37 patients with uterine leiomyosarcoma at a high-volume cancer center vol.12, pp.3, 2015, https://doi.org/10.4274/tjod.33602
  2. Clinical outcomes of tissue expanders on adjuvant radiotherapy of resected retroperitoneal sarcoma vol.95, pp.28, 2015, https://doi.org/10.1097/md.0000000000004123
  3. Uterine sarcoma Part I-Uterine leiomyosarcoma: The Topic Advisory Group systematic review vol.55, pp.4, 2015, https://doi.org/10.1016/j.tjog.2016.04.033
  4. Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08) vol.27, pp.6, 2016, https://doi.org/10.3802/jgo.2016.27.e58
  5. Distribution and survival of primary sarcoma in Korea: A single center analysis of 2017 cases vol.14, pp.1, 2015, https://doi.org/10.14216/kjco.18005
  6. Uterine Sarcomas: Surgical Management, Adjuvant Therapy and Survival Outcome. Experience at Gujarat Cancer and Research Institute vol.17, pp.1, 2015, https://doi.org/10.1007/s40944-018-0247-0
  7. Hormonal therapy in uterine sarcomas vol.8, pp.4, 2015, https://doi.org/10.1002/cam4.2044
  8. The Outcomes of Uterine Sarcoma: A Case-series of 5-Years Survey vol.4, pp.3, 2015, https://doi.org/10.30699/jogcr.4.3.120
  9. The pretreatment erythrocyte sedimentation rate predicts survival outcomes after surgery and adjuvant radiotherapy for extremity soft tissue sarcoma vol.14, pp.1, 2015, https://doi.org/10.1186/s13014-019-1331-z
  10. Adjuvant Radiotherapy Improved Survival in Stage I to II Low-Grade Endometrial Stromal Sarcoma: A Retrospective Study of 152 Cases vol.10, pp.None, 2015, https://doi.org/10.3389/fonc.2020.608152